Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AlloVir, Inc. - Common Stock (NQ:ALVR)

9.810 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AlloVir, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of AlloVir, Inc. (ALVR) Investors
From Kirby McInerney LLP
Via Business Wire
News headline image
ROSEN, A LONGSTANDING LAW FIRM, Encourages AlloVir, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR
From Rosen Law Firm
Via Business Wire
News headline image
ALLOVIR, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against AlloVir, Inc. (NASDAQ: ALVR)
From Bernstein Liebhard LLP
Via GlobeNewswire
AlloVir Inc. (NASDAQ: ALVR) Near the Top of Equities by Percentage Gain on 8/21
Via Investor Brand Network
News headline image
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Reports Third Quarter 2023 Financial Results
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir to Present at Upcoming Investor Conferences
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Reports Second Quarter 2023 Financial Results
From AlloVir, Inc.
Via Business Wire
News headline image
MarketBeat Week in Review – 7/10 - 7/14
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week 
Via MarketBeat
Topics Economy
News headline image
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
News headline image
AlloVir Announces Pricing of Public Offering of Common Stock
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Announces Proposed Public Offering of Common Stock
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
From AlloVir
Via Business Wire
News headline image
AlloVir Reports First Quarter 2023 Financial Results
From AlloVir
Via Business Wire
News headline image
AlloVir to Present at the BofA Securities 2023 Health Care Conference
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
From AlloVir
Via Business Wire
News headline image
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir to Participate in the SVB Securities Global Biopharma Conference
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
From AlloVir
Via Business Wire
News headline image
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
From AlloVir
Via Business Wire
News headline image
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Reports Third Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Reports Second Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
News headline image
AlloVir Announces $126.6 Million Registered Direct Offering
From AlloVir, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.